戻る
Abbisko Cayman Limited (02256.HK)価格
02256.HK 株価推移チャート
ABBISKO-B (02256.HK)
Abbisko Cayman Limited
HK$14.5
1.68%
$0.24
休場: Jan 16, 16:00:00 HKT
データなしEarnings FAQ
02256.HKの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Abbisko Cayman Limited 02256.HKの前四半期の収益はどうでしたか？
Abbisko Cayman Limitedの収益見積もりはいくらですか？
Abbisko Cayman Limitedの収益品質スコアはどれくらいですか？
Abbisko Cayman Limitedはいつ収益を報告しますか？
Abbisko Cayman Limitedの予想収益はいくらですか？
Abbisko Cayman Limitedは収益予想を上回りましたか？
主要データ
前終値
$14.73
始値
$14.26
当日レンジ
$14.25 - $14.69
52週レンジ
$4.2 - $19.78
取引高
658.0K
平均取引高
2.4M
1株当たり利益(TTM)
0.26
配当利回り
--
時価総額
$9.5B
ABBISKO-Bとは何ですか？
Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai and currently employs 226 full-time employees. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).